Company
introduction
introduction
Dongsung pharmaceutical with 60 years of history provides customer oriented total services and future oriented marketing which covers cosmetics and finished medicine.
| Product name | : | Avasta Tab. |
|---|---|---|
| Product division | : | ETC drug |
| Classification group | : | Circulatory medication |
| Insurance code | : | 643202370 |
| Efficacy and effect | : | 1. Reduction of risk for .. |
Basic information
-
- Appearance
- White oval film-coated tablet
-
- DOSAGE AND ADMINISTRATION
-
Patient who will be taking or is taking atorvastatin should have standard low cholesterol diet. The drug can be administered regardless of food, anytime throughout the day.
1. Hyperlipidemia
Recommended initial dose is 10mg, as atrovastatin, once a day, but for patient who require more LDL-cholesterol reduction, initial dose can be 20mg once a day or 40 mg(in case that requires 45 % LDL-cholesterol reduction.). This drug is administered in range of 10 ～ 80 mg once a day.
The initial dose and maintenance dose shoudl be customized depending on character of patient while considering therapeutic goal and reaction, and after starting medication and/or dose adjustment, lipid values are to be analyzed within 2 ～ 4 weeks, and dose should be adjusted accordingly.
Goal of therapy is to decrease LDL-cholesterol, and using LDL-cholesterol is recommended when starting the treatment or evaluating the response to treatment. However, when LDL-cholesterol value cannot be acquired, total cholesterol is used to monitor the response.
Homozygous familial hypercholesterolemia patient
Medication capacity of this drug is 10 ～ 80 mg once per day. It can be combined with other lipid lowering treatment (e.g., LDL apheresis) or be used if such lipid lowering treatment is impossible.
2. Child heterozygous familial hypercxholesterolemia patient (10 ～ 17)
Recommended inital dose is 10 mg a day and recommended maximum dose is 20 mg per day (in child patients, there is no clinical data that administered more than 20 mg of this drug.). Administering dose is appropriately adjusted based on therapeutic goal recommended in individual patient. Dose should be adjusted with interval of 4 weeks or more 용.
- Renal dysfunction patient: Renal disease does not affect serum concentration of atorvastatin or lowering of LDL-cholesterol, there is no need for dose adjustment.
- Elderly: Effectiveness and safety for old patient group in 70 or older are similar to normal adult patient group.
-
- Ingredient / content
-
per 1 tablet
- Atorvastatin calcium 10.36mg (10mg as atorvastatin)
-
- standard
- 30 tablet, 100 tablet
-
- How to Save
- Airtight container, Stored at room temperature(1~30℃)
-
- Efficacy and effect
-
1. Reduction of risk for following cardiovascular diseases
1) Though there is no clinical evidence for coronary disease, in adult patients with multiple risk factors for coronary disease (age > 55, smoking, hypertension, low HDL-cholesterol, or familial history of early coronary disease)
(1) reduces risk for myocardiac infarction
(2) Reduces risk for stroke
(3) Reduces risk for angioplasty and chronic stable angina
2) Though there is no clinical evidence for oronary disease, in type 2 DM patients with multiple risk factors for coronary disease (retinopathy, albuminuria, smoking, or hypertension, etc.)
(1) reduces risk for myocardiac infarction
(2) Reduces risk for stroke
3) In adult patient with clinical evidence of coronary disease
(1) Reduces risk for non-lethal myocardial infarction
(2) Reduces risk for lethal and non-lethal stroke
(3) Reduces risk for angioplasty
(4) Reduces risk for admission due to congestive heart failure
(5) Reduces risk for angina
2. Hyperlipidemia
E18
3) Dietary supplement for patients with high serum triglyceride(Fredrickson Type IV)
4) When other lipid lowering agent (e.g. LDL-apheresis) is simultaneously used or treatment with other lipid lowering agents cannot reduce total cholesterol and LDL-cholesterol in homozygous familial hypercholesterolemia
3. Dietary supplement that reduces total cholesterol, LDL-cholesterol, and Apo-B protein in child patients in age of 10~ 17 with heterozygous familial hypercholesterolemia that meets criteria of below despite dietary treatment(For women, patient after menarche)
A. When LDL-cholesterol is still 190 mg/dL or higher (≥1+E1990 mg/dL) or
B. When LDL-cholesterol is still 160 mg/dL or higher (≥160 mg/dL), and the patient has familial history for early cardiac disease or the child patient has two or more different risk factors for cardiovascular disease
DONGSUNG BIO PHARM SNS
